GlassScriptPhysician profile
Robert L Flowers
NPI 1619264371
$4,055.46
in general payments reported to CMS, 2019-2025
31 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $179 · 2021: $556 · 2022: $869 · 2023: $494 · 2024: $570 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,010.44 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $463.43 | 2019-2025 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $374.79 | 2022-2025 | Xifaxan |
| Novo Nordisk INC | $357.11 | 2019-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $209.89 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.05 | 2019-2023 | |
| Glaxosmithkline, LLC. | $195.74 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $158.06 | 2024-2025 | Rexulti |
| Amgen INC. | $157.29 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $122.29 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $109.27 | 2022 | |
| Lilly USA, LLC | $99.68 | 2019-2022 | |
| Horizon Therapeutics Plc | $93.36 | 2021-2022 | |
| Pfizer INC. | $77.17 | 2019-2022 | |
| Exact Sciences Corporation | $50.30 | 2024-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $43.67 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $41.84 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.63 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $33.81 | 2024-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $32.20 | 2023-2024 | Myrbetriq, Veozah |
| Sanofi-Aventis U.S. LLC | $25.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.41 | 2021 | |
| Phathom Pharmaceuticals, INC. | $21.27 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $20.19 | 2025 | Injectafer |
| Ironwood Pharmaceuticals, INC | $18.16 | 2021 | |
| Allergan, INC. | $16.01 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.57 | 2021 | |
| Radius Health, INC. | $13.61 | 2020 | |
| Genentech USA, INC. | $12.80 | 2020 | |
| Eisai INC. | $11.60 | 2019 | |
| Acadia Pharmaceuticals INC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Flowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.